HCW Biologics (NASDAQ:HCWB – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare HCW Biologics to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
Valuation & Earnings
This table compares HCW Biologics and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| HCW Biologics | $6.72 million | -$7.96 million | -0.03 |
| HCW Biologics Competitors | $764.04 million | $10.42 million | -17.98 |
HCW Biologics’ rivals have higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of recent ratings for HCW Biologics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
| HCW Biologics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
HCW Biologics presently has a consensus price target of $30.00, indicating a potential upside of 3,904.81%. As a group, “Biotechnology” companies have a potential upside of 114.50%. Given HCW Biologics’ higher probable upside, equities research analysts plainly believe HCW Biologics is more favorable than its rivals.
Risk and Volatility
HCW Biologics has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, HCW Biologics’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Insider & Institutional Ownership
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares HCW Biologics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HCW Biologics | -83.03% | -194.06% | -35.22% |
| HCW Biologics Competitors | -12,519.20% | -215.47% | -31.42% |
Summary
HCW Biologics rivals beat HCW Biologics on 8 of the 13 factors compared.
HCW Biologics Company Profile
HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies designed to address chronic inflammation, which the company views as a contributor to aging and age-related diseases. Its research also includes potential treatments for cancer and other serious conditions. The company uses proprietary biologics platforms to discover and develop engineered therapeutic candidates. Its pipeline includes investigational fusion-protein therapies intended to modulate immune activity; these candidates remain under clinical development and are not approved for commercial use.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
